http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Sung Ha Lee,Jae Do Yang,Hong Pil Hwang,Hee Chul Yu,Baik Hwan Cho 한국간담췌외과학회 2012 한국간담췌외과학회지 Vol.16 No.2
Backgrounds/Aims: The aim of this study is to analyze surgical outcomes and prognostic factors affecting survival after surgical resection in patients with gallbladder cancer. Methods: We retrospectively reviewed 86 patients treated surgically for gallbladder cancer from January 2000 to December 2009 at Chonbuk National University Hospital. Clinicopathologic factors, surgical treatment and outcome data were analyzed. Results: Among the 86 patients (44 male, 42 female) with gallbladder cancer, the mean age was 62.9 years (range: 32-80) and the median survival was 42.4±3.5 month. The overall cumulative survival rates of 86 patients were for 1 year, 83.7%; 3 year, 67.4%; 5 year survival, 61.7%. Univariate analysis revealed that preoperative serum alanine aminotransferase, alkaline phosphatase, total bilirubin, carcinoembryonic antigen (CEA), T staging, N staging were statistically significantly associated with survival. CEA (p=0.004) and T staging (p=0.005) were associated with survival in multivariate analysis. Two-year survival rates were analyzed according to the methods of surgical resection, with simple cholecystectomy showing 100%, whereas extended cholecystectomy showed about 83% in T1b. We could not find out any adverse effect of the simple cholecystectomy for survival. Conclusions: CEA and T stage are independent significant prognostic factor associated with patient survival in our study. Simple cholecystectomy can be regarded as curative resection in stage T1b. Longer observation periods and more cases will be needed to confirm these conclusions. (Korean J Hepatobiliary Pancreat Surg 2012;16:59-64)
Sang O Park,Young Bum Yoo,Yong Hun Kim,Kwang Je Baek,Jung-Hyun Yang,Pil Cho Choi,Jeong Hun Lee,Kyeong Ryong Lee,Kyoung Sik Park 대한외과학회 2015 Annals of Surgical Treatment and Research(ASRT) Vol.88 No.2
Purpose: The anticancer property and cytoprotective role of selenium in chemotherapy have been reported. However, the combination effects of selenium on chemotherapy for advanced breast cancer have not yet been clearly defined. The purpose of this study was to investigate the combined effects of selenium on chemotherapy using docetaxel on breast cancer cell lines. Methods: Under adherent culture conditions, two breast cancer cell lines, MDA-MB-231 and MCF-7, were treated with docetaxel at 500pM and selenium at 100nM, 1μM, or 10μM. Changes in cell growth, cell cycle duration, and degree of apoptosis after 72 hours in each treated group were evaluated. Results: In the MDA-MB-231 cells, the combination therapy group (docetaxel at 500pM plus selenium at 10mM) showed a significantly decreased percentage of cell growth (15% vs. 28%; P = 0.004), a significantly increased percentage of late apoptosis (63% vs. 26%; P = 0.001), and an increased cell cycle arrest in the G2/M phase (P = 0.001) compared with the solitary docetaxel therapy group. Isobologram analysis demonstrated the synergistic effect of the combination therapy in the MDA-MB-231 cells. However, in the MCF-7 cells, no significant differences in the percentage of cell growth apoptosis, the percentage of apoptosis, and the pattern of cell cycle arrest were noted between the combination therapy groups and the solitary docetaxel therapy group. Conclusion: Our in vitro study indicated that the combination of selenium with docetaxel inhibits cell proliferation through apoptosis and cell arrest in the G2/M phase in MDA-MB-231 breast cancer cells.
Pil-Sung Yang,정보영,Jaehan Jeong,So-Jeong You,Hee Tae Yu,김태훈,Jung-Hoon Sung,Sang-Soo Lee,Hyung-Deuk Park 대한심장학회 2019 Korean Circulation Journal Vol.49 No.8
Background and Objectives: There are limited published data on the incidence and cost associated with cardiac implantable electrical device (CIED) infection for Asian patients. We analyzed the infection burden associated with the implantation of CIEDs in Korea. Methods: In the Health Insurance Review & Assessment Service (HIRA) database during the period from January 1, 2014 to December 31, 2016, we identified 16,908 patients with CIED implantation. CIED infection was defined as either: 1) Infection-related diagnosis code by the Korean Standard Classification of Diseases after any CIED procedure; or 2) CIED removal along with systemic infection. Results: The proportions of first implantation and replacement were 77.6% and 22.4%, respectively. During the follow-up period of 17.1±10.6 months, a total of 462 patients had CIED infection with incidence of 1.95 per 100 person-years with higher infection rate in replacement than first implantation (3.97 vs. 1.4 per 100 person-years, p<0.001). The average cost per person was US$ 16,584 (pacemaker, $13,736; implantable cardioverter defibrillator, $28,402; cardiac resynchronization therapy, $29,674). The risk factors of CIED infection were generator replacement (adjusted hazard ratio [aHR], 3.14; 95% confidence interval [CI], 2.60–3.78), diabetes mellitus (aHR, 1.94; 95% CI, 1.58–2.38), and congestive heart failure (aHR, 1.86; 95% CI, 1.51–2.28). Conclusions: The rate of CIED infection in Korea was 1.95 per 100 person-years with average cost of US$ 16,584. The most important risk factor was generator replacement. This result suggests that generator replacement should be performed cautiously to avoid CIED infection.
Sang Eun Park,Sung Ha Lee,Jae Do Yang,Hong Pil Hwang,Si Eun Hwang,Hee Chul Yu,Woo Sung Moon,Baik Hwan Cho 한국간담췌외과학회 2013 한국간담췌외과학회지 Vol.17 No.4
Backgrounds/Aims: Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) is an uncommon subtype of primary liver cancer that has rarely been reported in detail. This study was performed in order to evaluate the clinicopathological characteristics and prognostic factors of cHCC-CC in single center. Methods: The clinicopathological features of patients diagnosed and operated with cHCC-CC at Chonbuk National Hospital between July 1998 and July 2007 were retrospectively studied by comparing them with patients with only hepatocellular carcinoma (HCC) who had undergone a hepatic resection during the same period. Results: Ten out of 152 patients who had undergone a hepatic resection were diagnosed with cHCC-CC and thus included in this study (M : F=8 : 2, median age: 52±11.1 years). According to the parameters of the 7th American Joint Committee on Cancer T staging, there were 76 (50.0%), 44 (28.9%), 9 (5.9%), 18 (11.8%) and 5 (3.3%) patients with T stages 1, 2, 3a, 3b and 4, respectively. The overall survival period was longer in the HCC only group (68±40.4 months) than in the combined cHCC-CC group (23±40.1 months) (p<0.0001). The 5-year survival rate was 10% in the cHCC-CC group and 60% in the HCC group (p<0.0001). The disease free survival for patients with cHCC-HCC and HCC were 16±37.4 and 51±44.3 months, respectively (p<0.0001). Univariate analysis revealed that age, gender, transarterial chemoembolization (TACE), and T stage were statistically significant in terms of patient’s overall survival. However, there were no significant clinicopathological factors identified by the multivariate analysis. Conclusions: Even after the hepatic resection in the HCC, the prognosis is poorer if the patient has cholangiocellular components compared to the usual HCC.
Yang, Jae Jeong,Cho, Lisa Y.,Lim, Yun Jeong,Ko, Kwang-Pil,Lee, Kun-Sei,Kim, Hyeongsu,Yim, Sung Vin,Chang, Soung Hoon,Park, Sue K. Mary Ann Liebert 2010 Journal of women's health Vol.19 No.2
<P>The aim of this study was to investigate the role of the estrogen receptor 1 (ESR1) genetic polymorphisms for early menopause that was classified as premature ovarian failure (POF) and early menopause (EM) and to examine whether the associations of ESR1 genetic variants are different for POF and EM.</P>
Yang, Jae Jeong,Yang, Ji Hyun,Kim, Jungkon,Ma, Seung Hyun,Cho, Lisa Y.,Ko, Kwang‐,Pil,Shin, Aesun,Choi, Bo Youl,Kim, Hyun Ja,Han, Dong Soo,Eun, Chang Soo,Song, Kyu Sang,Kim, Yong Sung,Chang, Sou Wiley Subscription Services, Inc., A Wiley Company 2013 International journal of cancer: Journal internati Vol.132 No.9
<P><B>Abstract</B></P><P>This study was conducted to evaluate the relevance of the soluble form of c‐Met protein, a truncated form of the c‐Met membrane receptor involved in the CagA pathway, as a potential biomarker for gastric cancer. Among 290 gastric cancer case‐control sets selected from the Korean Multicenter Cancer Cohort, the plasma concentrations of soluble c‐Met protein were measured with enzyme‐linked immunosorbent assays. Using analysis of variance and covariance models with age, sex, smoking, <I>Helicobacter pylori</I> infection, and CagA seropositivity, the mean concentrations of soluble c‐Met protein between cases and controls were compared. To evaluate the association between gastric cancer and a c‐Met protein level, odds ratios and 95% confidence intervals were estimated using conditional logistic regression models. Interactions between CagA‐related genes and the soluble c‐Met protein concentration were also investigated. The overall median plasma concentration of soluble c‐Met among cases was significantly lower than those of controls (1.390 <I>vs</I>. 1.610 ng/mL, <I>p</I> < 0.0001). Closer to the onset of gastric cancer, the soluble c‐Met protein level decreased linearly in a time‐dependent manner (<I>p</I> for trend = 0.0002). The combined effects between the CagA‐related genes and the soluble c‐Met protein concentration significantly intensified risks for gastric cancer. Restricted analyses including cases that had been diagnosed within 1 year after entering the cohort had a fair degree of ability (area under the receiver operating characteristic curve of 0.73–0.77) to discriminate gastric cancer cases from normal controls. Our findings demonstrate the potential of the soluble form of c‐Met protein as a novel biomarker for gastric cancer. The beneficial effects of a high soluble c‐Met concentration in human plasma are strongly supported.</P>
Yang, Jeong Hoon,Hahn, Joo-Yong,Song, Pil Sang,Song, Young Bin,Choi, Seung-Hyuk,Choi, Jin-Ho,Lee, Sang Hoon,Jeong, Myung-Ho,Choi, Dong-Joo,Kim, Young Jo,Gwon, Hyeon-Cheol by the Society of Critical Care Medicine and Lippi 2014 Critical care medicine Vol.42 No.1
OBJECTIVES:: We investigated the clinical impact of multivessel percutaneous coronary intervention in ST-segment elevation myocardial infarction complicated by cardiogenic shock with multivessel disease. DESIGN:: A prospective, multicenter, observational study. SETTING:: Cardiac ICU of a university hospital. PATIENTS:: Between November 2005 and September 2010, 338 patients were selected. Inclusion criteria were as follows: 1) ST-segment elevation myocardial infarction with cardiogenic shock and 2) multivessel disease with successful primary percutaneous coronary intervention for the infarct-related artery. Patients were divided into multivessel percutaneous coronary intervention and culprit-only percutaneous coronary intervention. INTERVENTIONS:: None. MEASUREMENTS AND MAIN RESULTS:: Primary outcome was all-cause mortality. Median follow-up duration was 224 days (interquartile range, 46–383 d). Multivessel percutaneous coronary intervention was performed during the primary percutaneous coronary intervention in 60 patients (17.8%). In-hospital mortality was similar in both groups (multivessel percutaneous coronary intervention vs culprit-only percutaneous coronary intervention, 31.7% vs 24.5%; p = 0.247). All-cause mortality during follow-up was not significantly different between the two groups after adjusting for patient, angiographic, and procedural characteristics as well as propensity scores for receiving multivessel percutaneous coronary intervention (35.0% vs 30.6%; adjusted hazard ratio, 1.06; 95% CI, 0.61–1.86; p = 0.831). There were no significant differences between the groups in rates of major adverse cardiac events (41.7% vs 37.1%; adjusted hazard ratio, 1.03; 95% CI, 0.62–1.71; p = 0.908) and any revascularization (6.7% vs 4.7%; adjusted hazard ratio, 1.88; 95% CI, 0.51–6.89; p = 0.344). CONCLUSIONS:: Multivessel percutaneous coronary intervention could not reduce the prevalence of mortality in patients with cardiogenic shock complicating ST-segment elevation myocardial infarction and multivessel disease during primary percutaneous coronary intervention.